EUVIMEDEUVIMED entdecken
Crossref

Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq

Huan Lu, Huafeng Wang, Qiwei Wang, Deyu Huang, Yingli Han, Hui Wang, Penglei Jiang, Xinyue Qian, Liping Mao, Min Yang, Hongyan Tong, Jie Jin und 2 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Huan Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology of the First Affiliated Hospital, Liangzhu Laboratory, Zhejiang University School of Medicine, Center for Stem Cell and Rege…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the key R&D program of zhejiang, the department of science and technology of zhejiang province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite extensive investigation into venetoclax resistance mechanisms in acute myeloid leukemia (AML), the dynamics of bone marrow (BM) microenvironment remodeling during venetoclax-based therapies remain poorly characterized at single-cell resolution. Using paired single-cell RNA sequencing of BM specimens from AML patients undergoing DAV therapy (venetoclax/decitabine/cytarabine; pre- vs post-treatment), we systematically mapped therapy-induced transcriptional reprogramming, regulatory network alterations, and niche crosstalk across clinical response subgroups. Our analysis revealed two pivotal mechanisms governing therapeutic outcomes: First, pre-existing immune-activating niches marked by elevated HLA class I presentation synergized with therapy-enhanced CD8+ T cell cytotoxicity and reduced tumor-promoting stroma-leukemia interactions to facilitate favorable responses. Second, responder leukemic cells exhibited transposable element (TE)-associated type I interferon signaling upregulation. Primitive leukemic clones displayed IMPDH2-high states linked to BCL2 inhibitor sensitivity, while resistant monocytic populations upregulated glycolysis and MCL1 to bypass BCL2 dependence. Leveraging these insights, we established a prognostic signature predicting patient responses to venetoclax-based therapies, validated in independent cohorts (Tumor Profiler, BeatAML2). High-risk patients identified by this signature demonstrated heightened sensitivity to IGF-1R inhibition. Functional validation in an established resistant cell line model confirmed that IGF-1R inhibition synergized with DAV by suppressing glucose uptake and differentiation. This study provides a comprehensive single-cell atlas of BM microenvironment evolution during venetoclax-based therapy, proposes a prognostic biomarker, and identifies a clinically actionable strategy to overcome therapeutic resistance in AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicDrug Resistance, NeoplasmHumansSingle-Cell AnalysisRNA-SeqTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsGene Expression Regulation, LeukemicCell Line, TumorFemaleSingle-Cell Gene Expression Analysis

Stichwörter der Autor:innen

Acute myeloid leukemiaDAV treatmentSingle-cell RNA sequencingTherapeutic resistanceVenetoclax

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology of the First Affiliated Hospital, Liangzhu Laboratory, Zhejiang University School of Medicine, Center for Stem Cell and Regenerative Medicine, Hangzhou, 310003, China; Institute of Hematology, Z…
  • Department of Hematology of the First Affiliated Hospital, Liangzhu Laboratory, Zhejiang University School of Medicine, Center for Stem Cell and Regenerative Medicine, Hangzhou, 310003, China; Zhejiang Provincial Key La…

Förderung

  • National Natural Science Foundation of China
  • the key R&D program of zhejiang
  • the department of science and technology of zhejiang province
  • International Science and Technology Cooperation Programme
  • Zhejiang University
  • the fundamental Research funds for the central universities
  • the zhejiang provincial natural science foundation of china
  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Lu, H., Wang, H., Wang, Q., Huang, D., Han, Y., Wang, H., Jiang, P., Qian, X., Mao, L., Yang, M., Tong, H., Jin, J., Qian, P., & Zhu, H. H. (2025). Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217853

Vancouver

Lu H, Wang H, Wang Q, Huang D, Han Y, Wang H, et al. Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217853

BibTeX
@article{Lu2025,
  author = {Lu, Huan and Wang, Huafeng and Wang, Qiwei and Huang, Deyu and Han, Yingli and Wang, Hui and Jiang, Penglei and Qian, Xinyue and Mao, Liping and Yang, Min and Tong, Hongyan and Jin, Jie and Qian, Pengxu and Zhu, Hong-Hu},
  title = {Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217853}
}
Kostenlos starten →